AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16276165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (n = 150)
Number of subjects: 300
Study 11925375 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic oral contraceptive (norethindrone 500 microg/ethinyl estradiol 35 microg for 10 days, followed by norethindrone 1000 microg/ethinyl estradiol 35 microg for 11 days)
Number of subjects: 1014
Study 11925375 — intervention group
Group type: COMPARATOR
Intervention: Monophasic oral contraceptive (norethindrone acetate 1500 microg/ethinyl estradiol 30 microg daily)
Number of subjects: 1014
Study 10190921 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg/d for 3 days)
Number of subjects: 50
Study 10190921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8871356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 8871356 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0
Study 8871356 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study 2406782 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response audiotape
Number of subjects: 45
Study 2406782 — intervention group
Group type: COMPARATOR
Intervention: Contemporary instrumental music audiotape
Number of subjects: 45
Study 2406782 — intervention group
Group type: COMPARATOR
Intervention: Blank audiotape
Number of subjects: 45
Study 7022849 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Medrol)
Number of subjects: 65
Study 7022849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 65
Study 30068285 — intervention group
Group type: EXPERIMENTAL
Intervention: Free triiodothyronine
Number of subjects: 486
Study 30068285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid peroxidase antibodies
Number of subjects: 486
Study 28714733 — intervention group
Group type: EXPERIMENTAL
Intervention: pure-PTP jury type
Number of subjects: 648
Study 28714733 — intervention group
Group type: EXPERIMENTAL
Intervention: mixed-PTP jury type
Number of subjects: 648
Study 28714733 — intervention group
Group type: COMPARATOR
Intervention: no PTP exposure
Number of subjects: 648
Study 28714733 — intervention group
Group type: EXPERIMENTAL
Intervention: PTP exposure
Number of subjects: 648
Study 28714733 — intervention group
Group type: EXPERIMENTAL
Intervention: different PTP slants
Number of subjects: 648
Study 28714733 — intervention group
Group type: EXPERIMENTAL
Intervention: deliberating with others who do not share similar biases
Number of subjects: 648
Study 26016820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg donepezil
Number of subjects: 74
Study 26016820 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC capsule taken while fasting
Number of subjects: 74
Study 26016820 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC contents sprinkled on applesauce while fasting
Number of subjects: 74
Study 26016820 — intervention group
Group type: COMPARATOR
Intervention: Co-administered memantine ER and donepezil
Number of subjects: 74
Study 25628196 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural drainage, tapping and tracheal aspiration (Group 1)
Number of subjects: 29
Study 25628196 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural drainage, expiratory acceleration flow and tracheal aspiration (Group 2)
Number of subjects: 29
Study 25628196 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Group 1 and Group 2)
Number of subjects: 29
Study 21996634 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program (SPRING) including exercise classes, nutrition classes, and bathing, twice a week for 3 months
Number of subjects: 60
Study 19512980 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18
Study 19512980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17200909 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (both)
Number of subjects: 32
Study 15356304 — intervention group
Group type: COMPARATOR
Intervention: Environmental intervention tailored to each child's allergic sensitization and environmental risk factors, lasting one year, including education and remediation for exposure to allergens and environmental tobacco smoke.
Number of subjects: 937
Study 15356304 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental intervention
Number of subjects: 937
Study 11592358 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) 20 mg/day, loading dose 100 mg x 3 days
Number of subjects: 235
Study 11592358 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 235
Study 11592358 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 235
Study 9555919 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial body weight support with treadmill locomotion (32% body weight supported) during comfortable walking, fast walking, and running for 6 weeks.
Number of subjects: 1
Study 9555919 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements taken for 6 weeks (phase AI) and a 3-week period without treatment (phase AII).
Number of subjects: 1
Study 7850536 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic breast biopsy with a 14-gauge needle
Number of subjects: 416
Study 7850536 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic breast biopsy followed by surgical biopsy
Number of subjects: 416
Study 3138445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (infusion between 5 pm and 9 am)
Number of subjects: 12
Study 3138445 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous total parenteral nutrition (infusion 24 hr/day)
Number of subjects: 12
Study 3138445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition
Number of subjects: 12
Study 3138445 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous total parenteral nutrition
Number of subjects: 12
Study 31752643 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC)
Number of subjects: 1114
Study 31752643 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1114
Study 28064113 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dLPFC) at 2mA for 30 minutes, 10 sessions over 10 consecutive days
Number of subjects: 24
Study 28064113 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control group)
Number of subjects: 24
Study 25927522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aseptic, purified, cryopreserved, infectious P. falciparum sporozoites (Sanaria® PfSPZ Challenge) administered intramuscularly (IM)
Number of subjects: 28
Study 23306147 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 1078
Study 23306147 — intervention group
Group type: COMPARATOR
Intervention: Oral rivastigmine
Number of subjects: 1078
Study 22129897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lipoceutical glutathione
Number of subjects: 26
Study 22129897 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glutathione
Number of subjects: 26
Study 18023600 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 40 mcg inhaled via MDI
Number of subjects: 47
Study 18023600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 mcg inhaled via MDI plus ondansetron 8 mg oral, qid, for 2 days
Number of subjects: 47
Study 18023600 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide placebo
Number of subjects: 47
Study 18023600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (single or repeated doses)
Number of subjects: 47
Study 18023600 — intervention group
Group type: EXPERIMENTAL
Intervention: sGaw
Number of subjects: 47
Study 18023600 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC
Number of subjects: 47
Study 16448522 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR (once-daily administration)
Number of subjects: 63
Study 16448522 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (twice-daily administration)
Number of subjects: 63
Study 14671407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2) per day (group A, n = 41)
Number of subjects: 165
Study 14671407 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg GH/m(2) per day (group B, n = 38)
Number of subjects: 165
Study 14671407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2) per day (n = 60)
Number of subjects: 165
Study 14671407 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 165
Study 14671407 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (1 mg or 2 mg GH/m(2) per day)
Number of subjects: 165
Study 14671407 — intervention group
Group type: EXPERIMENTAL
Intervention: After discontinuation of GH therapy
Number of subjects: 165
Study 14628975 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute aerobic endurance exercise at 60% workload
Number of subjects: 24
Study 14628975 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute aerobic endurance exercise at 40% workload
Number of subjects: 24
Study 14628975 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 24
Study 10193729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily for two weeks (phase I)
Number of subjects: 33
Study 10193729 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin average dose of 24 mg/d for three months (phase II)
Number of subjects: 33
Study 10193729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day added to simvastatin for two weeks (phase III)
Number of subjects: 33
Study 8589659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bithermal caloric stimulus
Number of subjects: 0
Study 8589659 — intervention group
Group type: COMPARATOR
Intervention: Traditional caloric irrigation
Number of subjects: 0
Study 1975526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0
Study 1975526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (calcium antagonist)
Number of subjects: 0
Study 342313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virus vaccine (H0N2)
Number of subjects: 1200
Study 342313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1200
Study 31495497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (300 mg intravenous on days 1 and 15)
Number of subjects: 230
Study 31495497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 31495497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 230
Study 28342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful-learning group
Number of subjects: 253
Study 28342402 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness condition
Number of subjects: 253
Study 28342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness group
Number of subjects: 253
Study 28342402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful-learning condition
Number of subjects: 253
Study 24917557 — intervention group
Group type: EXPERIMENTAL
Intervention: Unripe apple preparation containing phlorizin
Number of subjects: 6
Study 23627791 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound-specific oral nutrition supplement (enriched with arginine, vitamin C, and zinc)
Number of subjects: 24
Study 23627791 — intervention group
Group type: COMPARATOR
Intervention: Standard oral nutrition supplement
Number of subjects: 24
Study 23627791 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound-specific oral nutrition supplement
Number of subjects: 24
Study 20887370 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 10 mg
Number of subjects: 16
Study 20887370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg
Number of subjects: 16
Study 20887370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LZP) 2 mg
Number of subjects: 16
Study 20887370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19371826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC) (n = 25; glucose 80 to 140 mg/dl)
Number of subjects: 88
Study 19371826 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control (CGC) (n = 25; glucose 180 to 200 mg/dl)
Number of subjects: 88
Study 19371826 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemic patients compared to normoglycemic patients
Number of subjects: 88
Study 17693686 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatorade
Number of subjects: 8
Study 17693686 — intervention group
Group type: EXPERIMENTAL
Intervention: Apfelschorle
Number of subjects: 8
Study 17693686 — intervention group
Group type: EXPERIMENTAL
Intervention: San Benedetto mineral water
Number of subjects: 8
Study 17693686 — intervention group
Group type: COMPARATOR
Intervention: Evian mineral water
Number of subjects: 8
Study 15155310 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Group 1)
Number of subjects: 51
Study 15155310 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit (Group 2)
Number of subjects: 51
Study 11686425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 48
Study 10410575 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine levels in patients with MI without diabetes
Number of subjects: 0
Study 10410575 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine levels in patients with MI with diabetes
Number of subjects: 0
Study 10410575 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid indexes in patients with MI
Number of subjects: 0
Study 10410575 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of glucosamine levels and glucose concentrations in patients without diabetes
Number of subjects: 0
Study 10410575 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin levels in patients with hyperinsulinemia
Number of subjects: 0
Study 8290386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide
Number of subjects: 12
Study 8290386 — intervention group
Group type: COMPARATOR
Intervention: D-Trp-6-LHRH
Number of subjects: 12
Study 8290386 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age-matched controls)
Number of subjects: 12
Study 2845769 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP (cyclophosphamide 300 mg/m2 i.v., adriamycin 20 mg/m2 i.v., methotrexate 15 mg/m2 i.v. days 1 and 8, procarbazine 100 mg/m2 orally from day 1 to day 10, every 4 weeks)
Number of subjects: 133
Study 2845769 — intervention group
Group type: COMPARATOR
Intervention: DE (cisplatin 20 mg/m2 i.v. for five consecutive days and etoposide 75 mg/m2 i.v. on the same days, every 3 weeks)
Number of subjects: 133
Study 2845769 — intervention group
Group type: COMPARATOR
Intervention: DE
Number of subjects: 133
Study 2845769 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP
Number of subjects: 133
Study 31896735 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory positional therapy (PT)
Number of subjects: 40
Study 31896735 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 40
Study 31896735 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient treatment preference
Number of subjects: 40
Study 31320726 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVA device (Continuous Ambulatory Vestibular Assessment), worn near continuously for up to thirty days, with daily replacement of electrodes.
Number of subjects: 17
Study 28059849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin 60 mg/day)
Number of subjects: 69
Study 28059849 — intervention group
Group type: COMPARATOR
Intervention: Moderate statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Number of subjects: 69
Study 28059849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intensive and moderate statin therapy
Number of subjects: 69
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue countermeasures
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-avoidance strategies
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Call-shift fatigue
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical errors due to fatigue
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hours to recovery from a call shift
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Working 5 to 6 calls per month
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Working 7 or more calls per month
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of fatigue countermeasures
Number of subjects: 325
Study 26016171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue symptoms
Number of subjects: 325
Study 24028358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional team-based intervention featuring musical cues
Number of subjects: 1928
Study 24028358 — intervention group
Group type: COMPARATOR
Intervention: Comparison facilities (no musical cues)
Number of subjects: 1928
Study 21332970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate hydrochloride 1%
Number of subjects: 50
Study 21332970 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 50
Study 19298689 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (600 mg single dose) with nevirapine (200 mg every 12 h for 12 days)
Number of subjects: 14
Study 19298689 — intervention group
Group type: COMPARATOR
Intervention: Quinine (600 mg single dose) alone
Number of subjects: 14
Study 17974278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadaplatin 30 mg/m2 dl‐3, paclitaxol 175 mg/m2 dl, repeated every 4 weeks
Number of subjects: 60
Study 17974278 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 30 mg/m2 dl‐3, paclitaxol 175 mg/m2 dl, repeated every 4 weeks
Number of subjects: 60
Study 17974278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadaplatin combined with paclitaxol
Number of subjects: 60
Study 17974278 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin combined with paclitaxol
Number of subjects: 60
Study 15590950 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 674
Study 15590950 — intervention group
Group type: COMPARATOR
Intervention: Control (no ICD therapy)
Number of subjects: 674
Study 11561110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of triamcinolone hexacetonide and xylocaine
Number of subjects: 23
Study 11561110 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided injection of triamcinolone hexacetonide and xylocaine
Number of subjects: 23
Study 11561110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 23
Study 11561110 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided injection
Number of subjects: 23
Study 11561110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection and palpation-guided injection
Number of subjects: 23
Study 9460098 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic subjects
Number of subjects: 29
Study 9460098 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (N = 15)
Number of subjects: 29
Study 7888605 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolithic enteric coated (MEC) diclofenac products
Number of subjects: 16
Study 7888605 — intervention group
Group type: COMPARATOR
Intervention: Two mutually most differing MEC diclofenac products
Number of subjects: 16
Study 7888605 — intervention group
Group type: EXPERIMENTAL
Intervention: MEC diclofenac product with low tlag
Number of subjects: 16
Study 7888605 — intervention group
Group type: EXPERIMENTAL
Intervention: MEC diclofenac product with long tlag
Number of subjects: 16
Study 7888605 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dissolution tests at pH 5
Number of subjects: 16
Study 3062043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 22
Study 3062043 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 22
Study 3062043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30973454 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation ECT (4 weekly sessions, followed by 4 sessions every 2 weeks, and 2 monthly sessions for a total of 10 sessions)
Number of subjects: 0
Study 28478315 — intervention group
Group type: EXPERIMENTAL
Intervention: web intervention plus text messaging (WI+TXT)
Number of subjects: 113
Study 28478315 — intervention group
Group type: COMPARATOR
Intervention: assessment only (AO)
Number of subjects: 113
Study 28478315 — intervention group
Group type: COMPARATOR
Intervention: web intervention (WI)
Number of subjects: 113
Study 25251838 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group (MSoBT program)
Number of subjects: 50
Study 25251838 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (usual care)
Number of subjects: 50
Study 22594689 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge in a day unit
Number of subjects: 350
Study 22594689 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge at home
Number of subjects: 350
Study 22594689 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 350
Study 21459855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture bottle culture
Number of subjects: 62
Study 21459855 — intervention group
Group type: COMPARATOR
Intervention: Standard culture
Number of subjects: 62
Study 21459855 — intervention group
Group type: COMPARATOR
Intervention: Control fluids
Number of subjects: 62
Study 17373978 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm xenon chloride excimer laser therapy + topical calcipotriol (Daivonex) applied twice daily to one side of the body
Number of subjects: 10
Study 17373978 — intervention group
Group type: COMPARATOR
Intervention: 308-nm xenon chloride excimer laser therapy alone
Number of subjects: 10